Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients
May 11, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 28, 2022 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
April 13, 2022 08:52 ET
|
Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
Dyadic International to Present at Upcoming Scientific Medical Meetings
April 04, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Reports 2021 Year End Results and Recent Company Progress
March 29, 2022 16:00 ET
|
Dyadic International, Inc.
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American...
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
March 15, 2022 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
February 10, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
February 07, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
January 20, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...